BACKGROUND: Pulmonary hypertension (PH) is associated with a poor prognosis in idiopathic pulmonary fibrosis (IPF). Endothelin-1 (ET-1) and vascular endothelial growth factor (VEGF) are important in both fibrosis and vascular remodeling. OBJECTIVES: We sought to determine the relationship between ET-1 and VEGF levels and hemodynamics in patients with IPF. We hypothesized that higher levels of ET-1 and VEGF would be associated with higher pulmonary artery pressures (PAP) and pulmonary vascular resistance (PVR) in patients with IPF. METHODS: We performed a cross-sectional analysis of 52 adults with IPF enrolled in a prospective cohort with available clinical data, platelet-free plasma, and hemodynamics. ET-1 and VEGF levels were measured via immunoassay. The associations of ET-1 and VEGF with PAP and PVR were examined using generalized additive models adjusted for age, gender, race/ethnicity, and forced vital capacity (% predicted). RESULTS: Sixteen of 52 (30.8%) had PH (mean PAP ≥25 mm Hg). After multivariable adjustment, higher ET-1 levels were significantly associated with higher systolic (p = 0.01), diastolic (p = 0.02), and mean (p = 0.01) PAP and possibly higher PVR (p = 0.09). There were no significant associations between VEGF levels and hemodynamics. CONCLUSIONS: Higher levels of ET-1 were associated with higher PAP and possibly higher PVR in participants with IPF. In a subgroup of patients, ET-1 may be a contributor to pulmonary vascular disease burden in IPF.
BACKGROUND:Pulmonary hypertension (PH) is associated with a poor prognosis in idiopathic pulmonary fibrosis (IPF). Endothelin-1 (ET-1) and vascular endothelial growth factor (VEGF) are important in both fibrosis and vascular remodeling. OBJECTIVES: We sought to determine the relationship between ET-1 and VEGF levels and hemodynamics in patients with IPF. We hypothesized that higher levels of ET-1 and VEGF would be associated with higher pulmonary artery pressures (PAP) and pulmonary vascular resistance (PVR) in patients with IPF. METHODS: We performed a cross-sectional analysis of 52 adults with IPF enrolled in a prospective cohort with available clinical data, platelet-free plasma, and hemodynamics. ET-1 and VEGF levels were measured via immunoassay. The associations of ET-1 and VEGF with PAP and PVR were examined using generalized additive models adjusted for age, gender, race/ethnicity, and forced vital capacity (% predicted). RESULTS: Sixteen of 52 (30.8%) had PH (mean PAP ≥25 mm Hg). After multivariable adjustment, higher ET-1 levels were significantly associated with higher systolic (p = 0.01), diastolic (p = 0.02), and mean (p = 0.01) PAP and possibly higher PVR (p = 0.09). There were no significant associations between VEGF levels and hemodynamics. CONCLUSIONS: Higher levels of ET-1 were associated with higher PAP and possibly higher PVR in participants with IPF. In a subgroup of patients, ET-1 may be a contributor to pulmonary vascular disease burden in IPF.
Authors: M Yoshibayashi; K Nishioka; K Nakao; Y Saito; M Matsumura; T Ueda; S Temma; G Shirakami; H Imura; H Mikawa Journal: Circulation Date: 1991-12 Impact factor: 29.690
Authors: R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel Journal: J Pathol Date: 2001-10 Impact factor: 7.996
Authors: MeiLan K Han; David S Bach; Peter G Hagan; Eric Yow; Kevin R Flaherty; Galen B Toews; Kevin J Anstrom; Fernando J Martinez Journal: Chest Date: 2013-06 Impact factor: 9.410
Authors: Scott D Collum; Javier Amione-Guerra; Ana S Cruz-Solbes; Amara DiFrancesco; Adriana M Hernandez; Ankit Hanmandlu; Keith Youker; Ashrith Guha; Harry Karmouty-Quintana Journal: Can Respir J Date: 2017-02-13 Impact factor: 2.409
Authors: Jalpa Kotecha; Ludmila Shulgina; Darren W Sexton; Christopher P Atkins; Andrew M Wilson Journal: J Clin Med Date: 2016-09-07 Impact factor: 4.241